[go: up one dir, main page]

CR20130488A - Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia - Google Patents

Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia

Info

Publication number
CR20130488A
CR20130488A CR20130488A CR20130488A CR20130488A CR 20130488 A CR20130488 A CR 20130488A CR 20130488 A CR20130488 A CR 20130488A CR 20130488 A CR20130488 A CR 20130488A CR 20130488 A CR20130488 A CR 20130488A
Authority
CR
Costa Rica
Prior art keywords
arritmia
tieno
pyrimidine
treat
derivatives
Prior art date
Application number
CR20130488A
Other languages
English (en)
Inventor
Derek Edward John
John Ford
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44071904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130488(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of CR20130488A publication Critical patent/CR20130488A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos de tienopiridimidina que son inhibidores de canal de potasio. Composiciones farmacéuticas que comprenden los compuestos y su uso en el tratamiento de arritmia.
CR20130488A 2011-04-01 2013-09-26 Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia CR20130488A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds

Publications (1)

Publication Number Publication Date
CR20130488A true CR20130488A (es) 2013-12-06

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130488A CR20130488A (es) 2011-04-01 2013-09-26 Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia

Country Status (43)

Country Link
US (1) US9249155B2 (es)
EP (1) EP2694518B1 (es)
JP (1) JP5826374B2 (es)
KR (1) KR20140023332A (es)
CN (1) CN103492392B (es)
AP (1) AP2013007198A0 (es)
AR (1) AR088735A1 (es)
AU (1) AU2012235882B2 (es)
BR (1) BR112013025236A2 (es)
CA (1) CA2831493A1 (es)
CL (1) CL2013002789A1 (es)
CO (1) CO6801756A2 (es)
CR (1) CR20130488A (es)
CU (1) CU24173B1 (es)
CY (1) CY1117025T1 (es)
DK (1) DK2694518T3 (es)
EA (1) EA201301111A1 (es)
EC (1) ECSP13012988A (es)
ES (1) ES2558563T3 (es)
GB (1) GB201105659D0 (es)
GT (1) GT201300225A (es)
HK (2) HK1193096A1 (es)
HR (1) HRP20151340T1 (es)
HU (1) HUE028438T2 (es)
IL (1) IL228555A0 (es)
MA (1) MA35064B1 (es)
ME (1) ME02314B (es)
MX (1) MX335937B (es)
NI (1) NI201300100A (es)
PE (1) PE20141021A1 (es)
PH (1) PH12013501952A1 (es)
PL (1) PL2694518T3 (es)
PT (1) PT2694518E (es)
RS (1) RS54458B1 (es)
RU (1) RU2013148627A (es)
SG (1) SG193578A1 (es)
SI (1) SI2694518T1 (es)
SM (1) SMT201500322B (es)
TN (1) TN2013000377A1 (es)
TW (1) TWI516265B (es)
UA (1) UA110131C2 (es)
WO (1) WO2012131379A1 (es)
ZA (1) ZA201307085B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150307532A1 (en) * 2012-11-20 2015-10-29 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
EP0846119B1 (en) 1995-08-17 2002-11-13 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use as endothelin antagonists
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
CA2261143A1 (en) 1996-07-26 1998-02-05 Nissan Chemical Industries, Ltd. Chroman derivatives
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク． カリウムチャネル阻害剤
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
ATE311378T1 (de) 1999-09-17 2005-12-15 Nissan Chemical Ind Ltd Benzopyran derivate
EP1214307B1 (en) 1999-09-24 2004-04-07 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
AU7453900A (en) 1999-10-05 2001-05-10 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
JP2003518101A (ja) 1999-12-21 2003-06-03 アイカゲン インコーポレイテッド カリウムチャネル阻害剤
JP4854909B2 (ja) 2000-09-20 2012-01-18 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノン系カリウムチャンネル阻害剤
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
KR20030071880A (ko) 2001-02-02 2003-09-06 메르크 파텐트 게엠베하 피라졸로[４,３-ｄ]피리미딘과 엔도델린 수용체 길항제또는 티에노피리미딘과 엔도델린 수용체 길항제를포함하여 이루어지는 약제학적 조성물
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
EP1401823B1 (en) 2001-06-25 2005-10-05 Nissan Chemical Industries, Ltd. Substituted benzopyran derivatives against arrhythmia
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
ATE425982T1 (de) * 2003-06-11 2009-04-15 Xention Ltd Thienopyrimidin-derivate als kaliumkanal- inhibitoren
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
WO2005066182A1 (en) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
CA2571857A1 (en) 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
ATE476434T1 (de) 2004-12-09 2010-08-15 Xention Ltd Thienopyridinderivate als kaliumkanalinhibitoren
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
KR20090021218A (ko) * 2006-06-12 2009-02-27 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서 유용한 티에노피리미딘
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Also Published As

Publication number Publication date
PE20141021A1 (es) 2014-08-30
ES2558563T3 (es) 2016-02-05
MX335937B (es) 2016-01-04
US9249155B2 (en) 2016-02-02
CN103492392A (zh) 2014-01-01
AU2012235882B2 (en) 2015-08-06
CO6801756A2 (es) 2013-11-29
US20140206703A1 (en) 2014-07-24
AR088735A1 (es) 2014-07-02
CL2013002789A1 (es) 2014-07-18
SMT201500322B (it) 2016-02-25
CU24173B1 (es) 2016-04-25
PH12013501952A1 (en) 2018-04-11
NI201300100A (es) 2014-01-07
RU2013148627A (ru) 2015-05-10
TN2013000377A1 (en) 2015-01-20
JP2014509637A (ja) 2014-04-21
JP5826374B2 (ja) 2015-12-02
RS54458B1 (en) 2016-06-30
EP2694518B1 (en) 2015-10-07
HK1193096A1 (zh) 2014-09-12
NZ615621A (en) 2015-01-30
TW201244720A (en) 2012-11-16
GB201105659D0 (en) 2011-05-18
MA35064B1 (fr) 2014-04-03
DK2694518T3 (en) 2015-11-09
CN103492392B (zh) 2015-11-25
PT2694518E (pt) 2016-02-05
CU20130124A7 (es) 2014-01-29
HRP20151340T1 (hr) 2016-02-26
SG193578A1 (en) 2013-10-30
CA2831493A1 (en) 2012-10-04
BR112013025236A2 (pt) 2019-09-24
GT201300225A (es) 2014-12-30
ECSP13012988A (es) 2013-12-31
IL228555A0 (en) 2013-12-31
EP2694518A1 (en) 2014-02-12
UA110131C2 (ru) 2015-11-25
AU2012235882A1 (en) 2013-05-02
ME02314B (me) 2016-06-20
PL2694518T3 (pl) 2016-03-31
HK1193806A1 (zh) 2014-10-03
TWI516265B (zh) 2016-01-11
KR20140023332A (ko) 2014-02-26
AP2013007198A0 (en) 2013-10-31
SI2694518T1 (sl) 2016-02-29
ZA201307085B (en) 2015-04-29
MX2013011301A (es) 2014-04-16
CY1117025T1 (el) 2017-04-05
WO2012131379A1 (en) 2012-10-04
HUE028438T2 (en) 2017-02-28
EA201301111A1 (ru) 2014-02-28

Similar Documents

Publication Publication Date Title
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
MX2021000007A (es) Formulaciones de enzalutamida.
PH12016500024A1 (en) Bromodomain inhibitor
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
PE20151778A1 (es) Formulacion combinada de dos compuestos antivirales
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
AR089993A1 (es) Macrociclos peptidomimeticos
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
MX349796B (es) Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
GT201400111A (es) Triazolopiridinas sustituidas
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
GT201400017A (es) Derivados de piridin-2 (1h) -ona como inhibidores de jak
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
UY34018A (es) Derivados glucósidos y usos de los mismos
UA115357C2 (uk) Похідні піридин-4-ілу

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)